Decreased enthusiasm with this metabolic hypothesis has led to a shift in views regarding how SGLT2 inhibitors may elicit cardioprotection in T2D, with recent attention focused on the induction of autophagy [135]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.